Before its acquisition of Cubist Pharmaceuticals was barely underway, Merck's 9.5bn bid for the company already has garnered it a nice payoff – the US approval on 19 December of Zerbaxa (ceftolozane/tazobactam), a new combination antibiotic intended to treat adults with complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).
Shares of Cubist rose $2.08, or 2.1%, in after-hours trading on 19 December.





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
